CervoMed Files Routine 8-K; No Major Corporate Changes Reported

TL;DR

**CervoMed filed a standard 8-K with no major news, implying business as usual.**

AI Summary

CervoMed Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 5, 2024. This filing is a standard current report, indicating no major changes in leadership, compensatory arrangements, or other significant events that would typically be highlighted in an 8-K. For investors, this matters because the absence of significant news in this filing suggests business as usual, without any immediate red flags or catalysts for stock movement related to corporate governance or material events.

Why It Matters

This routine 8-K filing indicates no immediate material changes at CervoMed Inc., suggesting stability in corporate governance and operations, which can be reassuring for current and prospective investors.

Risk Assessment

Risk Level: low — The filing is routine and does not disclose any events that would inherently increase or decrease investment risk.

Analyst Insight

A smart investor would note the routine nature of this 8-K, indicating no immediate corporate governance or material event catalysts, and would look to other filings or news for more impactful information regarding CervoMed Inc.'s performance or strategic direction.

Key Players & Entities

• CervoMed Inc. (company) — the registrant filing the 8-K
• 001-37942 (other) — Commission File Number
• 30-0645032 (other) — I.R.S. Employer Identification No.
• February 5, 2024 (date) — Date of earliest event reported
• February 7, 2024 (date) — Date the 8-K was filed

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
• $5,078,500 — ain investors for aggregate proceeds of $5,078,500 and, in December 2021, EIP issued conve
• $6,000,000 — ain investors for aggregate proceeds of $6,000,000. Dr. Boger and certain affiliated trust
• $500,000 — and certain affiliated trusts purchased $500,000 of the 2020 Notes and $5,000,000 of the
• $5,000,000 — urchased $500,000 of the 2020 Notes and $5,000,000 of the 2021 Notes. In June 2023, EIP a
• $1.47 — , establish a fixed conversion price of $1.47 with respect to any conversion in conne
• $694,286 — Dr. Boger for a total purchase price of $694,286. On August 16, 2023, in connection wit

Filing Documents

• crvo20240205_8k.htm (8-K) — 40KB
• ex_623386.htm (EX-99.1) — 18KB
• ex_622961.htm (EX-99.2) — 6KB
• logosmall.jpg (GRAPHIC) — 6KB
• 0001437749-24-003357.txt ( ) — 214KB
• crvo-20240205.xsd (EX-101.SCH) — 3KB
• crvo-20240205_def.xml (EX-101.DEF) — 11KB
• crvo-20240205_lab.xml (EX-101.LAB) — 15KB
• crvo-20240205_pre.xml (EX-101.PRE) — 11KB
• crvo20240205_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events Appointment of Joshua S. Boger, Ph.D., as Director and Chair of the Board On February 7, 2024, the Company issued a press release announcing the election of Dr. Boger as a director and as Chair of the Board. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Participation in Emerging Growth Conference 67 On February 5, 2024, the Company issued a press release announcing that members of the Company's senior management team will present at the Emerging Growth Conference 67 on Wednesday, February 7, 2024 at 3:50 p.m. ET. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant (Incorporated by reference to Exhibit 4.3 to the Company's Current Report on Form 8-K filed with the SEC on August 17, 2023) 99.1 Press Release issued February 7, 2024 announcing appointment of Joshua S. Boger as Chair of the Board 99.2 Press Release issued February 5, 2024 announcing participation in Emerging Growth Conference 67 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel 4

View Full Filing

View this 8-K filing on SEC EDGAR